摘要
1例48岁慢性乙型肝炎女性患者,服用恩替卡韦片0.5g/d治疗约15个月出现乏力、失眠症状及体重减轻。检测甲状腺功能:FT317.24 pmol/L,FT443.93 pmol/L,TSH0.009mU/L。考虑甲状腺功能亢进可能与恩替卡韦有关。停服恩替卡韦片,予以丙硫氧嘧啶,普萘洛尔,维生素B6治疗。后因失访,预后不详。
A 48-year-old women with chronic hepatitis B received entecavir 0.5 g daily for about 15 months, and then she developed asthenia, insomnia, and weight loss. Thyroid function tests revealed the following levels： FT3 17.24 pmol/L, FT4 43.93 pmol/L, and TSH 0. 009 mU/L. Hyperthyroidism is considered to be entecavir-associated. Entecavir was withdrawn, and propyhhiouracil, propranol, and vitamin B6 were given. Her prognosis was unknown because of lose to follow-up.
出处
《药物不良反应杂志》
2009年第4期286-287,共2页
Adverse Drug Reactions Journal
